Revolution Medicines, Inc. (RVMD) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$505.13M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$445.22M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$315.27M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$264.71M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$505.13M | (m) | (m) | (m) | $2.29M* | -$387.32M* | (m) | $394.92M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$445.22M | (m) | (m) | (m) | $1.54M | -$354.17M | (m) | $343.97M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$315.27M | (m) | (m) | (m) | $3.35M* | -$207.31M* | (m) | $262.51M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$264.71M | (m) | (m) | (m) | $7.45M* | -$221.76M* | (m) | $224.13M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$240.76M | (m) | (m) | (m) | $3.27M | -$194.44M | (m) | $205.75M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$175.71M | (m) | $0.00 | (m) | $3.52M* | -$130.42M* | (m) | $151.75M | (m) | $0.00 |
| 2024-06-30 | Reported | (m) | -$156.64M | (m) | $0.00 | (m) | $2.40M* | -$128.17M* | (m) | $134.93M | (m) | $0.00 |
| 2024-03-31 | Reported | (m) | -$140.86M | (m) | $0.00 | (m) | $3.17M | -$160.56M | (m) | $118.02M | (m) | $0.00 |
| 2023-09-30 | Reported | (m) | -$123.25M | (m) | $0.00 | (m) | $2.54M* | -$100.50M* | (m) | $107.73M | (m) | -$3.87M |
| 2023-06-30 | Reported | -$107.57M* | -$108.80M | $1.22M* | $3.82M | -2813.13%* | $1.12M* | -$67.12M* | (m) | $97.98M | (m) | $0.00 |
| 2023-03-31 | Reported | (m) | (m) | (m) | (m) | -1054.35% | $1.76M | -$62.39M | (m) | $68.95M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | (m) | (m) | (m) | -395.03% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | Reported | -$75.54M* | -$76.53M | $991.00K* | $3.36M | -2250.95%* | $3.52M* | -$51.74M* | (m) | $69.45M | (m) | -$297.00K |
| 2022-06-30 | Reported | -$61.16M* | -$62.09M | $931.00K* | $9.12M | -670.89%* | $2.53M* | -$55.72M* | (m) | $61.00M | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | (m) | (m) | (m) | -752.81% | $1.89M | -$55.16M | (m) | $56.49M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | (m) | (m) | (m) | -550.71% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | Reported | -$52.37M* | -$53.16M | $793.00K* | $1.10M | -4756.58%* | $454.00K* | -$36.59M* | (m) | $46.47M | (m) | $0.00 |
| 2021-06-30 | Reported | -$43.73M* | -$44.53M | $803.00K* | $8.70M | -502.78%* | $1.31M* | -$34.08M* | (m) | $45.94M | (m) | $0.00 |
| 2021-03-31 | Reported | (m) | (m) | (m) | (m) | -362.51% | $3.58M | -$37.25M | (m) | $40.86M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | (m) | (m) | (m) | -381.74% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | Reported | -$26.89M* | -$27.55M | $665.00K* | $12.66M | -212.35%* | $687.00K* | -$27.02M* | (m) | $34.87M | (m) | $0.00* |
| 2020-06-30 | Reported | -$27.34M* | -$27.98M | $640.00K* | $10.03M | -272.76%* | $474.00K* | -$19.99M* | (m) | $32.92M | (m) | -$58.00K |
| 2020-03-31 | Reported | (m) | (m) | (m) | (m) | -177.12% | $603.00K | -$28.02M | (m) | $27.46M | (m) | -$675.00K |
| 2019-12-31 | Reported | (m) | (m) | (m) | (m) | -156.90% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Reported | -$12.95M* | -$13.56M | $605.00K* | $12.51M | -103.58%* | $1.11M* | -$13.86M* | (m) | $22.96M | (m) | (m) |
| 2019-06-30 | Reported | -$10.02M* | -$10.56M | $544.00K* | $12.28M | -81.57%* | $631.00K* | -$11.50M* | (m) | $20.12M | (m) | (m) |
| 2019-03-31 | Reported | (m) | (m) | (m) | (m) | -75.27% | $341.00K | -$12.61M | (m) | $21.19M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$1.18B | (m) | $0.00 | (m) | $15.99M | -$897.74M | (m) | $987.33M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$689.52M | (m) | $0.00 | (m) | $10.31M | -$557.44M | (m) | $592.23M | (m) | -$753.00K |
| 2023-12-31 | Reported | (m) | -$487.19M | (m) | $11.58M | (m) | $7.73M | -$350.57M | (m) | $423.14M | (m) | -$3.52M |
| 2022-12-31 | Reported | (m) | (m) | (m) | (m) | -718.79% | $10.82M | -$224.40M | (m) | $253.07M | (m) | -$420.00K |
| 2021-12-31 | Reported | (m) | (m) | (m) | (m) | -629.21% | $6.53M | -$147.18M | (m) | $186.95M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | (m) | (m) | (m) | -251.46% | $2.93M | -$100.06M | (m) | $132.25M | (m) | -$371.00K |
| 2019-12-31 | Reported | (m) | (m) | (m) | (m) | -103.61% | $2.59M | -$49.62M | (m) | $91.75M | (m) | -$4.37M |
| 2018-12-31 | Reported | (m) | (m) | (m) | (m) | -192.23% | $1.50M | $1.21M | (m) | $51.08M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |